Results 171 to 180 of about 8,864 (209)

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors

Clinical Cancer Research
Abstract Purpose: Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]octreotate (177Lu-Dotatate) is an effective and safe treatment for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NET). Whereas 177Lu-Dotatate prolongs progression-free survival
Morticia N. Becx, Johannes Hofland, Eric P. Krenning, David K. Wyld, Julie Nonnekens, Frederik A. Verburg, Tessa Brabander, Jan J.V. van Busschbach, Wouter W. de Herder   +8 more
openaire   +5 more sources

Esthesioneuroblastoma (Olfactory Neuroblastoma) Treated With 111In-Octreotide and 177Lu-DOTATATE PRRT

Clinical Nuclear Medicine, 2015
A 51-year-old man with a recurrent metastatic esthesioneuroblastoma (olfactory neuroblastoma) was referred for peptide receptor radionuclide therapy (PRRT). He received 4 treatments of 111In-octreotide over 8 months and 3 treatments of 177Lu-DOTATATE over 4 months, which helped alleviate his symptoms and improved his quality of life; however, the tumor
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.

Oncology, 2011
Peptide receptor-targeted radionuclide therapy (PRRT) of somatostatin receptor (SR)-expressing neuroendocrine tumors (NETs) has become an established therapeutic option in patients with advanced NETs. The aim of this study was to compare the lesion detection rate of (99m)Tc-EDDA/HYNIC-TOC, a newly developed tracer for NET imaging, with (177)Lu-DOTATATE
Siroos, Mirzaei, Brigitte, Bastati, Rainer W, Lipp, Peter, Knoll, Niklas, Zojer, Heinz, Ludwig   +5 more
openaire   +1 more source

Extraventricular Neurocytoma Treated With 177Lu DOTATATE PRRT Induction and Maintenance Therapies

Clinical Nuclear Medicine, 2015
A 64-year-old woman with a 30-year history of recurrent sellar masses presented with severe headache and rapidly progressive visual field loss in the left eye. She was diagnosed with an extraventricular neurocytoma, which was octreotide positive, and was referred for PRRT (peptide receptor radionuclide therapy) with 177Lu [DOTA0,Tyr3]octreotate ...
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE

Medical Oncology, 2019
This is the first described case of effective and durable cytoreduction after PRRT with 177Lu-DOTATATE in a 75-year-old female, with B cell chronic lymphoid leukemia, and well-differentiated metastatic neuroendocrine tumor.
Savovic T, Prior JO, Nicod-Lalonde M, Bressoud A, Roux S, Schaefer N, Meyer M   +6 more
openaire   +3 more sources

¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors

New England Journal of Medicine, 2017
_To the Editor:_ Although the results of the multicenter, randomized, controlled Neuroendocrine Tumors Therapy (NETTER-1) trial reported by Strosberg et al. (Jan. 12 issue) validate the experience gained over the past decade by many institutions, we think that they overstate the toxic effects of lutetium-177 (177Lu)–Dotatate and potentially ...
Michael S, Hofman, Michael, Michael, Rodney J, Hicks   +2 more
openaire   +5 more sources

Evaluation of Peritoneal Fluid Extracted from Patients Administered 177Lu-DOTATATE

Health Physics
Abstract Patients experiencing ascites, the buildup of fluid in the peritoneal cavity, frequently undergo paracentesis to drain fluid from their peritoneal cavity via a peritoneal port. Some patients experiencing ascites may require nuclear medicine procedures to address other medical conditions.
Christopher, Helstern, Ling Hsiu, Chung, Kenneth, Lewis   +2 more
openaire   +2 more sources

Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: 177Lu-DOTATATE.

PET clinics, 2023
177Lu-DOTA-TATE therapy is a highly effective therapy in metastatic, well-differentiated, somatostatin receptor-positive GEP-neuroendocrine tumors (NETs) with mostly tolerable adverse effects. Guidelines generally refer to peptide receptor radionuclide therapy as a second-line therapy after SSA in gastroenteric and second- or third-line therapy in ...
Yasemin, Sanli, Dilara, Denizmen, Rathan M, Subramaniam   +2 more
openaire   +1 more source

[Indications and Practice of a New Radionuclide Therapy, 177Lu-DOTATATE in Japan].

Gan to kagaku ryoho. Cancer & chemotherapy, 2022
Peptide receptor radionuclide therapy(PRRT)is a pioneer drug in the rapid development of radio-theranostics, and a paradigm-shifting approach to treat neuroendocrine tumor( NET). The NETTER-1 trial for NETs of the midgut is currently the only global phase Ⅲ prospective clinical trial demonstrating the efficacy and safety of PRRT.
Shoko, Takano, Noritoshi, Kobayashi, Yasushi, Ichikawa, Masaharu, Hata   +3 more
openaire   +1 more source

Neuroendocrine tumor therapy with 177Lu-DOTATATE: the dosimetric approach

Physica Medica, 2021
A. Rienzo, E. Richetta, M. Poli, R.E. Pellerito, A. Codegone, M. Stasi   +5 more
openaire   +1 more source